Related references
Note: Only part of the references are listed.Supratherapeutic concentrations of cilostazol inhibits β-amyloid oligomerization in vitro
Hidenobu Shozawa et al.
NEUROSCIENCE LETTERS (2018)
Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study
Shu-Yu Tai et al.
NEUROTHERAPEUTICS (2017)
Cilostazol Suppresses Aβ-induced Neurotoxicity in SH-SY5Y Cells through Inhibition of Oxidative Stress and MAPK Signaling Pathway
Tatsunori Oguchi et al.
FRONTIERS IN AGING NEUROSCIENCE (2017)
Glucose deprivation increases tau phosphorylation via P38 mitogen-activated protein kinase
Elisabetta Lauretti et al.
AGING CELL (2015)
Cilostazol Add-On Therapy in Patients with Mild Dementia Receiving Donepezil: A Retrospective Study
Masafumi Ihara et al.
PLOS ONE (2014)
Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: A pilot study
Hirofumi Sakurai et al.
GERIATRICS & GERONTOLOGY INTERNATIONAL (2013)
Role of metabotropic glutamate receptor 5 signaling and homer in oxygen glucose deprivation-mediated astrocyte apoptosis
Maryse Paquet et al.
MOLECULAR BRAIN (2013)
The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception
Michael W. Weiner et al.
Alzheimers & Dementia (2011)
Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation
Sun Haeng Park et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments
Eric M. Reiman
NEUROBIOLOGY OF AGING (2011)
Neuroimaging in Dementia
Maria Carmela Tartaglia et al.
NEUROTHERAPEUTICS (2011)
Cilostazol prevents amyloid β peptide25-35-induced memory impairment and oxidative stress in mice
Masayuki Hiramatsu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R. Jack et al.
LANCET NEUROLOGY (2010)
CREB's control of intrinsic and synaptic plasticity: implications for CREB-dependent memory models
Eva Benito et al.
TRENDS IN NEUROSCIENCES (2010)
Cilostazol preserves CA1 hippocampus and enhances generation of immature neuroblasts in dentate gyrus after transient forebrain ischemia in rats
Jeong Hyun Lee et al.
EXPERIMENTAL NEUROLOGY (2009)
Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury
Jeong Hyun Lee et al.
CNS NEUROSCIENCE & THERAPEUTICS (2008)
Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease
Yi Li et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease
P. Hemachandra Reddy et al.
TRENDS IN MOLECULAR MEDICINE (2008)
Concurrent administration of cilostazol with donepezil effectively improves cognitive dysfunction with increased neuroprotection after chronic cerebral hypoperfusion in rats
Jeong Hyun Lee et al.
BRAIN RESEARCH (2007)
PDE inhibitors in psychiatry - future options for dementia, depression and schizophrenia?
Tobias B. Halene et al.
DRUG DISCOVERY TODAY (2007)
What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
W. Jagust et al.
NEUROLOGY (2007)
The phosphodiesterase inhibitor rolipram promotes survival of newborn hippocampal neurons after ischemia
Tsutomu Sasaki et al.
STROKE (2007)
Validation of the severe impairment battery for patients with Alzheimer's disease in Korea
Guk-Hee Suh et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2006)
Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion
Terubumi Watanabe et al.
STROKE (2006)
Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion
JH Lee et al.
BRAIN RESEARCH (2006)
Restoration of learning ability in hyperammonemic rats by increasing extracellular cGMP in brain
S Erceg et al.
BRAIN RESEARCH (2005)
Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer's disease treatment studies
GE Alexander et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Development of the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet (CERAD-K): Clinical and neuropsychological assessment batteries
JH Lee et al.
JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES (2002)
Positron emission tomography in evaluation of dementia - Regional brain metabolism and long-term outcome
DHS Silverman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
An energy budget for signaling in the grey matter of the brain
D Attwell et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2001)
Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET)
MJ de Leon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)